Antimicrobial peptides for bacterial infections and their biomedical applications
Source abstract
Abstract
Due to the rapid development of multidrug-resistant (MDR) bacteria due to the inappropriate use and misuse of antibiotics and the ineffective performance of antibiotics against refractory biofilm-associated infections (BRI), there is an urgent need for novel alternative antimicrobials and strategies to combat bacterial infections. Antimicrobial peptides (AMPs) have attracted considerable interest due to their potent activity against MDR pathogens and biofilm-associated infections, coupled with a substantially reduced risk of driving antimicrobial resistance-especially when employed as alternatives or adjuncts to conventional antibiotics. With the development of nanocarrier-based delivery strategies, AMP nanomaterials significantly improve the therapeutic effect of AMP by improving the hydrolytic stability, in vivo half-life, solubility, and reducing cytotoxicity and hemolysis of AMP. Distinct from previous reviews that primarily focus on AMP sequence engineering or generic nanocarrier types, this work adopts a clinically oriented framework organized by infection site-including pulmonary, bloodstream, gastrointestinal, chronic wound, and implant-associated infections. Key therapeutic outcomes reported in the literature are systematically compared, such as reductions in minimum inhibitory concentration (MIC), biofilm eradication efficiency, survival benefits in sepsis models, and wound closure kinetics. Formulation design strategies, administration routes, and the rational application of nanocarriers constructed from metallic elements, biocompatible polymers, and lipid-based architectures are discussed in the context of specific infectious microenvironments. By correlating the physicochemical properties of nanocarriers-such as surface charge, degradation profile, and release kinetics-with therapeutic performance across diverse infection models, this review also addresses the current limitations of AMP-based formulations in clinical applications. Overall, this review provides insights into the advantages and disadvantages of AMP-based nanomaterials currently under development for the treatment of bacterial infections in the literature, bringing inspiration and recommendations for their future design.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Antimicrobial Peptides and Activities · Antimicrobial agents and applications · Bacterial biofilms and quorum sensing
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Zhao C, Liu J, Li B, et al. Multiscale construction of bifunctional electrocatalysts for long-lifespan rechargeable zinc–air batteries. Adv Funct Mater. 2020;30:2003619. https://doi.org/10.1002/adfm.202003619.10.1002/adfm.202003619 ↗
2. Zhao Z, Yan R, Yi X, et al. Bacteria-activated theranostic nanoprobes against methicillin-resistant Staphylococcus aureus Infection. ACS Nano. 2017;11:4428–38. https://doi.org/10.1021/acsnano.7b00041.10.1021/acsnano.7b00041 ↗
3. Lin M, Sun J. Antimicrobial peptide-inspired antibacterial polymeric materials for biosafety. Biosaf Health. 2022;4:269–79. https://doi.org/10.1016/j.bsheal.2022.03.009.10.1016/j.bsheal.2022.03.009 ↗
4. Zhu X, Radovic-Moreno AF, Wu J, et al. Nanomedicine in the management of microbial infection – Overview and perspectives. Nano Today. 2014;9:478–98. https://doi.org/10.1016/j.nantod.2014.06.003.10.1016/j.nantod.2014.06.003 ↗
5. Fjell CD, Hiss JA, Hancock REW, Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov. 2012;11:37–51. https://doi.org/10.1038/nrd3591.10.1038/nrd3591 ↗
6. Neshani A, Zare H, Akbari Eidgahi MR, et al. Review of antimicrobial peptides with anti- Helicobacter pylori activity. Helicobacter. 2019;24:e12555. https://doi.org/10.1111/hel.12555.10.1111/hel.12555 ↗
7. Jenssen H, Hamill P, Hancock REW. Peptide antimicrobial agents. Clin Microbiol Rev. 2006;19:491–511. https://doi.org/10.1128/CMR.00056-05.10.1128/CMR.00056-05 ↗
8. Kim H, Jang JH, Kim SC, Cho JH. Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa. Eur J Med Chem. 2020;185:111814. https://doi.org/10.1016/j.ejmech.2019.111814.10.1016/j.ejmech.2019.111814 ↗
9. Guo Y, Gao F, Rafiq M, et al. Preparation of antimicrobial peptides and their combination with hydrogels for wound healing applications. Int J Biol Macromol. 2024;274:133494. https://doi.org/10.1016/j.ijbiomac.2024.133494.10.1016/j.ijbiomac.2024.133494 ↗
10. Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011;29:464–72. https://doi.org/10.1016/j.tibtech.2011.05.001.10.1016/j.tibtech.2011.05.001 ↗
11. Yin Q, Wu S, Wu L, et al. A novel in silico antimicrobial peptide DP7 combats MDR Pseudomonas aeruginosa and related biofilm infections. J Antimicrob Chemother. 2020;75:3248–59. https://doi.org/10.1093/jac/dkaa308.10.1093/jac/dkaa308 ↗
12. Lee H-R, You D, Kim HK, et al. Romo1-Derived antimicrobial peptide is a new antimicrobial agent against multidrug-resistant bacteria in a murine model of sepsis. mBio. 2020;11:e03258–19. https://doi.org/10.1128/mBio.03258-19.10.1128/mBio.03258-19 ↗
13. Sani M-A, Separovic F. How membrane-active peptides get into lipid membranes. Acc Chem Res. 2016;49:1130–8. https://doi.org/10.1021/acs.accounts.6b00074.10.1021/acs.accounts.6b00074 ↗
14. Jiang Y, Chen Y, Song Z, et al. Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation. Adv Drug Deliv Rev. 2021;170:261–80. https://doi.org/10.1016/j.addr.2020.12.016.10.1016/j.addr.2020.12.016 ↗
15. Wang Y, Zhao L, Li Z, et al. A generative artificial intelligence approach for the discovery of antimicrobial peptides against multidrug-resistant bacteria. Nat Microbiol. 2025;10:2997–3012. https://doi.org/10.1038/s41564-025-02114-4.10.1038/s41564-025-02114-4 ↗
16. Ngashangva N, Huidrom S, Devi IS. Antimicrobial peptides: natural templates for next-generation therapeutics against antimicrobial resistance. Front Cell Infect Microbiol. 2026;15:1720027. https://doi.org/10.3389/fcimb.2025.1720027.10.3389/fcimb.2025.1720027 ↗
17. De La Fuente-Núñez C, Reffuveille F, Haney EF, et al. Broad-spectrum anti-biofilm peptide that targets a cellular stress response. PLoS Pathog. 2014;10:e1004152. https://doi.org/10.1371/journal.ppat.1004152.10.1371/journal.ppat.1004152 ↗
18. Serna N, Sánchez-García L, Sánchez-Chardi A, et al. Protein-only, antimicrobial peptide-containing recombinant nanoparticles with inherent built-in antibacterial activity. Acta Biomater. 2017;60:256–63. https://doi.org/10.1016/j.actbio.2017.07.027.10.1016/j.actbio.2017.07.027 ↗
19. De Breij A, Riool M, Cordfunke RA, et al. The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. Sci Transl Med. 2018;10:eaan4044. https://doi.org/10.1126/scitranslmed.aan4044.10.1126/scitranslmed.aan4044 ↗
20. Mwangi J, Yin Y, Wang G, et al. The antimicrobial peptide ZY4 combats multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii infection. Proc Natl Acad Sci USA. 2019;116:26516–22. https://doi.org/10.1073/pnas.1909585117.10.1073/pnas.1909585117 ↗
21. Thankappan B, Thomas A, Sakthivadivel A, et al. In vitro and in vivo antimicrobial activity of self-assembled melittin nanoparticles: A comparative study with melittin peptide. Colloids Surf B. 2023;226:113331. https://doi.org/10.1016/j.colsurfb.2023.113331.10.1016/j.colsurfb.2023.113331 ↗
22. Cho J, Hong H-W, Park K, et al. Unveiling the mechanism of bactericidal activity of a cecropin A-fused endolysin LNT113. Int J Biol Macromol. 2024;260:129493. https://doi.org/10.1016/j.ijbiomac.2024.129493.10.1016/j.ijbiomac.2024.129493 ↗
23. Tolos AM, Moisa C, Dochia M, et al. Anticancer potential of antimicrobial peptides: focus on buforins. Polymers. 2024;16:728. https://doi.org/10.3390/polym1606072810.3390/polym16060728 ↗
24. Parthasarathy A, Borrego EJ, Savka MA, et al. Amino acid–derived defense metabolites from plants: a potential source to facilitate novel antimicrobial development. J Biol Chem. 2021;296:100438. https://doi.org/10.1016/j.jbc.2021.100438.10.1016/j.jbc.2021.100438 ↗
25. Brunner SR, Varga JFA, Dixon B. Antimicrobial peptides of salmonid fish: from form to function. Biology. 2020;9:233. https://doi.org/10.3390/biology9080233.10.3390/biology9080233 ↗
26. Jin Z, Shen M, Wang L, et al. Antibacterial and immunoregulatory activity of an antimicrobial peptide hepcidin in loach (Misgurnus anguillicaudatus). Int J Biol Macromol. 2023;242:124833. https://doi.org/10.1016/j.ijbiomac.2023.124833.10.1016/j.ijbiomac.2023.124833 ↗
27. Scott MG, Dullaghan E, Mookherjee N, et al. An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol. 2007;25:465–72. https://doi.org/10.1038/nbt1288.10.1038/nbt1288 ↗
28. Lázár V, Martins A, Spohn R, et al. Antibiotic-resistant bacteria show widespread collateral sensitivity to antimicrobial peptides. Nat Microbiol. 2018;3:718–31. https://doi.org/10.1038/s41564-018-0164-0.10.1038/s41564-018-0164-0 ↗
29. Revia RA, Stephen ZR, Zhang M. Theranostic nanoparticles for RNA-based cancer treatment. Acc Chem Res. 2019;52:1496–506. https://doi.org/10.1021/acs.accounts.9b00101.10.1021/acs.accounts.9b00101 ↗
30. Wang X, Sun Y, Wang F, et al. A novel endogenous antimicrobial peptide CAMP 211-225 derived from casein in human milk. Food Funct. 2020;11:2291–8. https://doi.org/10.1039/C9FO02813G.10.1039/C9FO02813G ↗
31. Schneider T, Kruse T, Wimmer R, et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor lipid II. Science. 2010;328:1168–72. https://doi.org/10.1126/science.1185723.10.1126/science.1185723 ↗
32. Dash R, Bhattacharjya S. Thanatin: An Emerging host defense antimicrobial peptide with multiple modes of action. IJMS. 2021;22:1522. https://doi.org/10.3390/ijms22041522.10.3390/ijms22041522 ↗
33. Ye Z, Zhu H, Zhang S, et al. Highly efficient nanomedicine from cationic antimicrobial peptide-protected Ag nanoclusters. J Mater Chem B. 2021;9:307–13. https://doi.org/10.1039/D0TB02267E.10.1039/D0TB02267E ↗
34. Van Der Weide H, Cossío U, Gracia R, et al. Therapeutic efficacy of novel antimicrobial peptide AA139-Nanomedicines in a multidrug-resistant Klebsiella pneumoniae Pneumonia-Septicemia Model in Rats. Antimicrob Agents Chemother. 2020;64:e00517–20. https://doi.org/10.1128/AAC.00517-20.10.1128/AAC.00517-20 ↗
35. Anguraj D, Chaudhary S, Pasupuleti M, et al. Modified SPPS protocol for the synthesis of novel antimicrobial peptides. Int J Pept Res Ther. 2025;31:63. https://doi.org/10.1007/s10989-025-10720-3.10.1007/s10989-025-10720-3 ↗
36. Yu W-S, Chen M-H, Ting C-L, et al. Stationary-phase antimicrobial peptide production in Escherichia coli. Probiotics Antimicro Prot. 2025. https://doi.org/10.1007/s12602-025-10517-2.10.1007/s12602-025-10517-2 ↗
37. Dong C, Li M, Zhang R, et al. The Expression of antibacterial peptide Turgencin a in Pichia Pastoris and an analysis of its antibacterial activity. Molecules. 2023;28:5405. https://doi.org/10.3390/molecules28145405.10.3390/molecules28145405 ↗
38. Humpola MV, Spinelli R, Erben M, et al. D- and N-Methyl amino acids for modulating the therapeutic properties of antimicrobial peptides and lipopeptides. Antibiotics. 2023;12:821. https://doi.org/10.3390/antibiotics12050821.10.3390/antibiotics12050821 ↗
39. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discovery Today. 2010;15:40–56. https://doi.org/10.1016/j.drudis.2009.10.009.10.1016/j.drudis.2009.10.009 ↗
40. Mahlapuu M, Björn C, Ekblom J. Antimicrobial peptides as therapeutic agents: opportunities and challenges. Crit Rev Biotechnol. 2020;40:978–92. https://doi.org/10.1080/07388551.2020.1796576.10.1080/07388551.2020.1796576 ↗
41. Liu J, Zhou Y, Lyu Q, et al. Targeted protein delivery based on stimuli-triggered nanomedicine. Exploration. 2024;4:20230025. https://doi.org/10.1002/EXP.20230025.10.1002/EXP.20230025 ↗
42. Thapa RK, Diep DB, Tønnesen HH. Topical antimicrobial peptide formulations for wound healing: current developments and future prospects. Acta Biomater. 2020;103:52–67. https://doi.org/10.1016/j.actbio.2019.12.025.10.1016/j.actbio.2019.12.025 ↗
43. Wang S, Yan C, Zhang X, et al. Antimicrobial peptide modification enhances the gene delivery and bactericidal efficiency of gold nanoparticles for accelerating diabetic wound healing. Biomater Sci. 2018;6:2757–72. https://doi.org/10.1039/C8BM00807H.10.1039/C8BM00807H ↗
44. Casciaro B, Moros M, Rivera-Fernández S, et al. Gold-nanoparticles coated with the antimicrobial peptide esculentin-1a(1–21)NH2 as a reliable strategy for antipseudomonal drugs. Acta Biomater. 2017;47:170–81. https://doi.org/10.1016/j.actbio.2016.09.041.10.1016/j.actbio.2016.09.041 ↗
45. Pranantyo D, Liu P, Zhong W, et al. Antimicrobial peptide-reduced gold nanoclusters with charge-reversal moieties for bacterial targeting and imaging. Biomacromolecules. 2019;20:2922–33. https://doi.org/10.1021/acs.biomac.9b00392.10.1021/acs.biomac.9b00392 ↗
46. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116:2602–63. https://doi.org/10.1021/acs.chemrev.5b00346.10.1021/acs.chemrev.5b00346 ↗
47. Hultmark D. Drosophila immunity: paths and patterns. Curr Opin Immunol. 2003;15:12–9. https://doi.org/10.1016/S0952-7915(02)00005-5.10.1016/S0952-7915(02)00005-5 ↗
48. Barra D, Simmaco M. Amphibian skin: A promising resource for antimicrobial peptides. Trends Biotechnol. 1995;13:205–9. https://doi.org/10.1016/S0167-7799(00)88947-7.10.1016/S0167-7799(00)88947-7 ↗
49. Yao L, Liu Q, Lei Z, Sun T. Development and challenges of antimicrobial peptide delivery strategies in bacterial therapy: A review. Int J Biol Macromol. 2023;253:126819. https://doi.org/10.1016/j.ijbiomac.2023.126819.10.1016/j.ijbiomac.2023.126819 ↗
50. Sirtori LR, Motta ADSD, Brandelli A. Mode of action of antimicrobial peptide P45 on Listeria monocytogenes. J Basic Microbiol. 2008;48:393–400. https://doi.org/10.1002/jobm.200700406.10.1002/jobm.200700406 ↗
51. Fearon DT, Locksley RM. The instructive role of lnnate lmmunity in the acquired immune response.Science.1996;272:50.10.1126/science.272.5258.50 ↗
52. Moriyama B, Henning SA, Leung J, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. 2012;55:290–7. https://doi.org/10.1111/j.1439-0507.2011.02158.x.10.1111/j.1439-0507.2011.02158.x ↗
53. Olli S, Nagaraj R, Motukupally SR. A hybrid cationic peptide composed of human β-Defensin-1 and humanized θ-Defensin sequences exhibits salt-resistant antimicrobial activity. Antimicrob Agents Chemother. 2015;59:217–25. https://doi.org/10.1128/AAC.03901-14.10.1128/AAC.03901-14 ↗
54. Park G, Yun H, Min HJ, Lee CW. A novel dimeric short peptide derived from α-defensin-related Rattusin with improved antimicrobial and DNA-binding activities. Biomolecules. 2024;14:659. https://doi.org/10.3390/biom14060659.10.3390/biom14060659 ↗
55. Batista Araujo J, De Sastre G, Lorenzon EN. Indolicidin revisited: biological activity, potential applications and perspectives of an antimicrobial peptide not yet fully explored. World J Microbiol Biotechnol. 2022;38:39. https://doi.org/10.1007/s11274-022-03227-2.10.1007/s11274-022-03227-2 ↗
56. Song X, Liu P, Liu X, et al. Dealing with MDR bacteria and biofilm in the post-antibiotic era: Application of antimicrobial peptides-based nano-formulation. Mater Sci Engineering: C. 2021;128:112318. https://doi.org/10.1016/j.msec.2021.112318.10.1016/j.msec.2021.112318 ↗
57. Mikhailova EO. Silver Nanoparticles: mechanism of action and probable bio-application. JFB. 2020;11:84. https://doi.org/10.3390/jfb11040084.10.3390/jfb11040084 ↗
58. Liu J, Zhou Y, Lyu Q, et al. Targeted protein delivery based on stimuli-triggered nanomedicine. Exploration. 2024;4:20230025. https://doi.org/10.1002/EXP.20230025.10.1002/EXP.20230025 ↗
59. Liu H, Yu Y, Dong A, et al. Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: systematic review, improvements and future challenges. Exploration. 2024;4:20230092. https://doi.org/10.1002/EXP.20230092.10.1002/EXP.20230092 ↗
60. Geng Z, Cao Z, Liu J. Recent advances in targeted antibacterial therapy basing on nanomaterials. Exploration. 2023;3:20210117. https://doi.org/10.1002/EXP.20210117.10.1002/EXP.20210117 ↗
61. Kim YJ, Lee J-Y, Lee JJ, et al. Arginine-mediated gut microbiome remodeling promotes host pulmonary immune defense against nontuberculous mycobacterial infection. Gut Microbes. 2022;14:2073132. https://doi.org/10.1080/19490976.2022.2073132.10.1080/19490976.2022.2073132 ↗
62. Liang Y, He J, Guo B. Functional hydrogels as wound dressing to enhance wound healing. ACS Nano. 2021;15(8):12687.10.1021/acsnano.1c04206 ↗
63. Xia X, Yin Z, Yang Y, et al. In situ upregulating heat shock protein 70 via gastric nano-heaters for the interference of helicobacter pylori infection. ACS Nano. 2022;16(9):14043.10.1021/acsnano.2c03911 ↗
64. Yu Q, Deng T, Lin F-C, et al. Supramolecular assemblies of heterogeneous mesoporous silica nanoparticles to co-deliver antimicrobial peptides and antibiotics for synergistic eradication of pathogenic biofilms. ACS Nano. 2020;14:5926–37. https://doi.org/10.1021/acsnano.0c01336.10.1021/acsnano.0c01336 ↗
65. Ju X, Chen J, Zhou M, et al. Combating Pseudomonas aeruginosa Biofilms by a Chitosan-PEG-peptide conjugate via changes in assembled structure. ACS Appl Mater Interfaces. 2020;12(12):1373110.1021/acsami.0c02034 ↗
66. Moulahoum H, Ghorbani Zamani F, Timur S, Zihnioglu F. Metal binding antimicrobial peptides in nanoparticle bio-functionalization: new heights in drug delivery and therapy. Probiotics Antimicro Prot. 2020;12:48–63. https://doi.org/10.1007/s12602-019-09546-5.10.1007/s12602-019-09546-5 ↗
67. Salazar-González JA, González-Ortega O, Rosales-Mendoza S. Gold nanoparticles and vaccine development. Expert Rev Vaccines. 2015;14:1197–211. https://doi.org/10.1586/14760584.2015.1064772.10.1586/14760584.2015.1064772 ↗
68. Singh S, Nimse SB, Mathew DE, et al. Microbial melanin: recent advances in biosynthesis, extraction, characterization, and applications. Biotechnol Adv. 2021;53:107773. https://doi.org/10.1016/j.biotechadv.2021.107773.10.1016/j.biotechadv.2021.107773 ↗
69. Thakor AS, Jokerst J, Zavaleta C, et al. Gold nanoparticles: a revival in precious metal administration to patients. Nano Lett. 2011;11:4029–36. https://doi.org/10.1021/nl202559p.10.1021/nl202559p ↗
70. Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621. https://doi.org/10.1038/ncomms6621.10.1038/ncomms6621 ↗
71. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280:22–35. https://doi.org/10.1016/j.cellimm.2012.11.009.10.1016/j.cellimm.2012.11.009 ↗
72. Comune M, Rai A, Chereddy KK, et al. Antimicrobial peptide-gold nanoscale therapeutic formulation with high skin regenerative potential. J Controlled Release. 2017;262:58–71. https://doi.org/10.1016/j.jconrel.2017.07.007.10.1016/j.jconrel.2017.07.007 ↗
73. Ferreira AF, Comune M, Rai A, et al. Atomistic-level investigation of a LL37-conjugated gold nanoparticle by well-tempered metadynamics. J Phys Chem B. 2018;122:8359–66. https://doi.org/10.1021/acs.jpcb.8b05717.10.1021/acs.jpcb.8b05717 ↗
74. Möhler JS, Sim W, Blaskovich MAT, Cooper MA, Ziora ZM. Silver bullets: A new lustre on an old antimicrobial agent. Biotechnol Adv. 2018;36(5):1391–411. https://doi.org/10.1016/j.biotechadv.2018.05.004.10.1016/j.biotechadv.2018.05.004 ↗
75. Ovais M, Ahmad I, Khalil AT, et al. Wound healing applications of biogenic colloidal silver and gold nanoparticles: recent trends and future prospects. Appl Microbiol Biotechnol. 2018;102:4305–18. https://doi.org/10.1007/s00253-018-8939-z.10.1007/s00253-018-8939-z ↗
76. Ambekar RS, Kandasubramanian B. Advancements in nanofibers for wound dressing: A review. Eur Polymer J. 2019;117:304–36. https://doi.org/10.1016/j.eurpolymj.2019.05.020.10.1016/j.eurpolymj.2019.05.020 ↗
77. Grimaldi N, Andrade F, Segovia N, et al. Lipid-based nanovesicles for nanomedicine. Chem Soc Rev. 2016;45:6520–45. https://doi.org/10.1039/C6CS00409A.10.1039/C6CS00409A ↗
78. Li X, Fan R, Tong A, Yang M, Deng J, Zhou L, Zhang X, Guo G. In situ gel-forming AP-57 peptide delivery system for cutaneous wound healing. Int J Pharm. 2015;495(1):560–71. https://doi.org/10.1016/j.ijpharm.2015.09.005.10.1016/j.ijpharm.2015.09.005 ↗
79. Luo G, Sun Y, Zhang J, et al. Nanodefensin-encased hydrogel with dual bactericidal and pro-regenerative functions for advanced wound therapy. Theranostics. 2021;11:3642–60. https://doi.org/10.7150/thno.53089.10.7150/thno.53089 ↗
80. Aida K, Kreling P, Caiaffa K, et al. Antimicrobial peptide-loaded liquid crystalline precursor bioadhesive system for the prevention of dental caries. IJN Volume. 2018;13:3081–91. https://doi.org/10.2147/IJN.S155245.10.2147/IJN.S155245 ↗
81. Durão J, Vale N, Gomes S, et al. Nitric oxide release from antimicrobial peptide hydrogels for wound healing. Biomolecules. 2018;9:4. https://doi.org/10.3390/biom9010004.10.3390/biom9010004 ↗
82. Obuobi S, Tay HK-L, Tram NDT, et al. Facile and efficient encapsulation of antimicrobial peptides via crosslinked DNA nanostructures and their application in wound therapy. J Controlled Release. 2019;313:120–30. https://doi.org/10.1016/j.jconrel.2019.10.013.10.1016/j.jconrel.2019.10.013 ↗
83. Riquelme SA, Ahn D, Prince A. Pseudomonas aeruginosa and Klebsiella pneumoniae adaptation to innate immune clearance mechanisms in the lung. J Innate Immun. 2018;10:442–54. https://doi.org/10.1159/000487515.10.1159/000487515 ↗
84. Malhotra S, Hayes D, Wozniak DJ. Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clin Microbiol Rev. 2019;32:e00138–18. https://doi.org/10.1128/CMR.00138-18.10.1128/CMR.00138-18 ↗
85. Curran CS, Bolig T, Torabi-Parizi P. Mechanisms and targeted therapies for Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med. 2018;197:708–27. https://doi.org/10.1164/rccm.201705-1043SO.10.1164/rccm.201705-1043SO ↗
86. Lim YH, Tiemann KM, Hunstad DA, et al. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. WIREs Nanomed Nanobiotechnol. 2016;8:842–71. https://doi.org/10.1002/wnan.1401.10.1002/wnan.1401 ↗
87. d’Angelo I, Casciaro B, Miro A, et al. Overcoming barriers in Pseudomonas aeruginosa lung infections: engineered nanoparticles for local delivery of a cationic antimicrobial peptide. Colloids Surf B. 2015;135:717–25. https://doi.org/10.1016/j.colsurfb.2015.08.027.10.1016/j.colsurfb.2015.08.027 ↗
88. Mygind PH, Fischer RL, Schnorr KM, et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature. 2005;437:975–80. https://doi.org/10.1038/nature04051.10.1038/nature04051 ↗
89. Gracia R, Marradi M, Cossío U, et al. Synthesis and functionalization of dextran-based single-chain nanoparticles in aqueous media. J Mater Chem B. 2017;5:1143–7. https://doi.org/10.1039/C6TB02773C.10.1039/C6TB02773C ↗
90. Water JJ, Smart S, Franzyk H, et al. Nanoparticle-mediated delivery of the antimicrobial peptide plectasin against Staphylococcus aureus in infected epithelial cells. Eur J Pharm Biopharm. 2015;92:65–73. https://doi.org/10.1016/j.ejpb.2015.02.009.10.1016/j.ejpb.2015.02.009 ↗
91. Elliott AG, Huang JX, Neve S, et al. An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria. Nat Commun. 2020;11:3184. https://doi.org/10.1038/s41467-020-16950-x.10.1038/s41467-020-16950-x ↗
92. Andrade F, Rafael D, Videira M, et al. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv Drug Deliv Rev. 2013;65:1816–27. https://doi.org/10.1016/j.addr.2013.07.020.10.1016/j.addr.2013.07.020 ↗
93. Hadinoto K, Cheow WS. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa. Colloids Surf B. 2014;116:772–85. https://doi.org/10.1016/j.colsurfb.2014.02.032.10.1016/j.colsurfb.2014.02.032 ↗
94. Doroudian M, O’ Neill A, Mac Loughlin R, et al. Nanotechnology in pulmonary medicine. Curr Opin Pharmacol. 2021;56:85–92. https://doi.org/10.1016/j.coph.2020.11.002.10.1016/j.coph.2020.11.002 ↗
95. Moreno-Sastre M, Pastor M, Esquisabel A, et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm. 2016;498:263–73. https://doi.org/10.1016/j.ijpharm.2015.12.028.10.1016/j.ijpharm.2015.12.028 ↗
96. LaPlante K, Cusumano J, Tillotson G. Colistin for the treatment of multidrug-resistant infections. Lancet Infect Dis. 2018;18:1174–5. https://doi.org/10.1016/S1473-3099(18)30611-X.10.1016/S1473-3099(18)30611-X ↗
97. Batoni G, Maisetta G, Lisa Brancatisano F, et al. Use of antimicrobial peptides against microbial biofilms: advantages and limits. CMC. 2011;18:256–79. https://doi.org/10.2174/092986711794088399.10.2174/092986711794088399 ↗
98. Jarry TM, Memmi G, Cheung AL. The expression of alpha-haemolysin is required for Staphylococcus aureus phagosomal escape after internalization in CFT-1 cells. Cell Microbiol. 2008;10:1801–14. https://doi.org/10.1111/j.1462-5822.2008.01166.x.10.1111/j.1462-5822.2008.01166.x ↗
99. Kodaman N, Pazos A, Schneider BG, et al. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci USA. 2014;111:1455–60. https://doi.org/10.1073/pnas.1318093111.10.1073/pnas.1318093111 ↗
100. Farrell P. Pathogenesis: Infections causing gastric cancer. Nat Microbiol. 2016;1:16038. https://doi.org/10.1038/nmicrobiol.2016.38.10.1038/nmicrobiol.2016.38 ↗